You are here
Award Data
The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.
Download all SBIR.gov award data either with award abstracts (290MB)
or without award abstracts (65MB).
A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.
The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.
-
Novel Combinations of Natural Product Compounds for Treatment of Alzheimer Disease and Related Dementias
SBC: Path Biotech, LLC Topic: NIAPROJECT SUMMARY/ABSTRACT In response to National Institute on Aging's (NIA) strategic plan and PAS-19-317, we propose novel therapeuticsto treat Alzheimer disease and related dementias (ADRDs). We have developed novel combinations of three natural product compounds, which modulate complementary pathways in multiple types of CNS cells (i.e., neurons, microglia) associated with AD pathology. These c ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
ICU-CARE: An interactive mobile app to enhance the efficiency of daily informal caregiving in the intensive care unit
SBC: SILICON CURES LLC Topic: NINRPROJECT SUMMARY Actively involving informal caregivers in direct patient care at the bedside in the intensive care unit (ICU) has the potential to improve patient, informal caregiver, and health care system outcomes. Practice guidelines call for the liberal inclusion of informal caregivers as active partners in ICU care, but there is a critical, unmet need to develop tools that effectively operati ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Minimally Invasive On Demand Electrical Nerve Block (OD-ENB) Device for Peripheral Pain
SBC: H-CUBED Topic: NIDAKnee Osteoarthritis (KOA) is a degenerative joint disease that leads to significant pain and functional disability affecting over 30% of older adults making it one of the most common and debilitating conditions related to aging. This disease results in a loss of mobility, reduced quality of life, and in ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Glycan biomarker panels in liquid biopsies for predicting treatment response in lupus nephritis
SBC: GLYCOPATH INC Topic: 400Lupus nephritis (LN), an immune complex-mediated glomerulonephritis, affects up to two-thirds of patients with systemic lupus erythematosus. Despite standard treatment protocols, progression of the most aggressive forms of LN (class III and IV) to end-stage renal failure remains high. Thus, there is a need for biomarkers of therapeutic response that would allow physicians to make better-informed t ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing natural compound emodin as a therapy for alcoholic cardiomyopathy
SBC: AcePre, LLC Topic: NIAAAProject Summary: Alcoholic Cardiomyopathy (ACM) is the most prevalent form of ethanol-induced heart damage. Alcohol dose-dependently induces ACM, characterized by progressive reduction in myocardial contractility and ventricular dilatation, culminating in heart failure. At the cellular level, chronic alcohol consumption results in cardiomyocyte death, cardiac inflammation, and cardiac fibrosis. Th ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
An Efficacy Trial of Mobile Technology for Reducing and Preventing Adolescent Suicide
SBC: OUI THERAPEUTICS INC Topic: 104ABSTRACT Suicide is a leading cause of death in the US and suicide rates have steadily increased. Despite this, there is a paucity of interventions that reduce suicide ideation and behavior. In this project, we seek to enhance a beta version of our suicide prevention digital therapeutic (developed in phase I) and conduct a randomized controlled trial to evaluate the efficacy of the digital therape ...
STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health -
Physics-informed Machine Learning approach for a selective, sensitive, and rapid sensor for detecting unsafe levels of carcinogenic/toxic VOCs
SBC: Prometheus Technologies, LLC Topic: NIEHSProject Summary Each year, between 340,000 and 900,000 premature deaths can be linked to air pollution caused by releasing Volatile Organic Compounds (VOCs), i.e., an estimated 1.8 billion tons of VOCs are emitted to the global environment each year. Also, some VOCs cause serious adverse health effects even at the trace level concentration, e.g., cancer, damage to the central nervous and immune sy ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Novel Therapeutics for Heart Failure: Modified, Water-Soluble Caveolin-1 Scaffolding Domain Peptides with Improved Characteristics for Drug Development
SBC: FIBROTHERAPEUTICS INC Topic: NHLBIAbstract Our long-term objective is to fill the unmet need for treatments for heart failure (HF). Caveolin-1 is a promising therapeutic target in fibrotic diseases. The profibrotic effects of caveolin-1 deficiency in cells and in mouse models is suppressed by a peptide equivalent to its active site (caveolin-1 scaffolding domain, CSD). We have shown the beneficial effects of CSD in two independent ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Preclinical Development of a Novel Therapeutic Agent for Idiopathic Pulmonary Fibrosis
SBC: FibroBiologics, LLC Topic: NHLBIIdiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease with a median survival of only 3 - 5 years from diagnosis. Although two FDA-approved drugs, pirfenidone and nintedanib, may slow the rate of decline of lung function in some IPF patients, neither drug significantly alters the course of this lethal disease. There is a great need for new drugs with greater efficacy and le ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health -
Developing novel LOX inhibitors to target chemotherapy resistant TNBC
SBC: LOXIGEN, INC. Topic: 102PROJECT SUMMARY Triple negative breast cancer (TNBC) is the most aggressive breast cancer subtype. It accounts for ~15% of all breast cancer yet is responsible for 30% of breast cancer deaths. TNBC is treated primarily by conventional chemotherapy; however, resistance to therapy is common, leading to high mortality rates. Importantly, the benefit of current therapeutic strategies used in chemoresi ...
STTR Phase I 2023 Department of Health and Human ServicesNational Institutes of Health